Xos (XOS) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 04, 2023
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-39598
Entity Registrant Name	XOS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-1550505
Entity Address, Address Line One	3550 Tyburn Street
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90065
City Area Code	818
Local Phone Number	316-1890
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		170,540,236
Amendment Flag	false
Entity Central Index Key	0001819493
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Common Stock
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	XOS
Security Exchange Name	NASDAQ
Warrants
Entity Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol	XOSWW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 36,489	$ 35,631
Restricted cash	0	3,044
Accounts receivable, net	6,970	8,238
Marketable debt securities, available-for-sale	27,528	50,648
Inventories	57,007	57,540
Prepaid expenses and other current assets	8,476	8,100
Total current assets	136,470	163,201
Property and equipment, net	17,752	18,581
Operating lease right-of-use assets, net	6,172	6,555
Other non-current assets	1,821	1,599
Total assets	162,215	189,936
Liabilities
Accounts payable	3,533	2,896
Convertible debt, current	19,635	26,849
Derivative liabilities	497	405
Other current liabilities	17,168	15,616
Total current liabilities	40,833	45,766
Convertible debt, non-current	19,882	19,870
Earn-out shares liability	616	564
Common stock warrant liability	666	661
Other non-current liabilities	10,467	11,000
Total liabilities	72,464	77,861
Commitment and Contingencies (Note 13)
Stockholders’ Equity
Common Stock $0.0001 par value, authorized 1,000,000 shares, 169,829 and 168,817 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	17	17
Preferred Stock $0.0001 par value, authorized 10,000 shares, 0 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	191,820	190,215
Accumulated deficit	(101,749)	(77,418)
Accumulated other comprehensive loss	(337)	(739)
Total stockholders’ equity	89,751	112,075
Total liabilities and stockholders’ equity	$ 162,215	$ 189,936

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	169,829,000	168,817,000
Common stock outstanding (in shares)	169,829,000	168,817,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenues	$ 4,697,000	$ 7,031,000
Cost of goods sold	5,574,000	13,030,000
Gross loss	(877,000)	(5,999,000)
Operating expenses
General and administrative	11,599,000	11,322,000
Research and development	5,749,000	6,949,000
Sales and marketing	1,804,000	2,028,000
Total operating expenses	19,152,000	20,299,000
Loss from operations	(20,029,000)	(26,298,000)
Other (expense) income, net	(4,151,000)	81,000
Change in fair value of derivative instruments	(97,000)	(435,000)
Change in fair value of earn-out shares liability	(52,000)	2,624,000
Loss before provision for income taxes	(24,329,000)	(24,028,000)
Provision for income taxes	2,000	2,000
Net loss	(24,331,000)	(24,030,000)
Marketable debt securities, available-for-sale
Net unrealized gain (loss), net of tax of $0, for the three months ended March 31, 2023 and 2022	402,000	(826,000)
Total comprehensive loss	$ (23,929,000)	$ (24,856,000)
Net loss per share
Net loss per share — basic (in dollar per share)	$ (0.14)	$ (0.15)
Net loss per share — diluted (in dollar per share)	$ (0.14)	$ (0.15)
Weighted average shares outstanding
Weighted average shares outstanding — basic (in shares)	168,829,000	163,165,000
Weighted average shares outstanding — diluted (in shares)	168,829,000	163,165,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021		163,137,000
Beginning balance at Dec. 31, 2021	$ 174,393	$ 16	$ 178,851	$ (4,093)	$ (381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation expense	1,068		1,068
Issuance of common stock for vesting of restricted stock units (in shares)		133,000
Shares withheld related to net share settlement of stock-based awards (in shares)		(36,000)
Shares withheld related to net share settlement of stock-based awards	(97)		(97)
Issuance of common stock for commitment shares under Standby Equity Purchase Agreement (in shares)		19,000
Issuance of common stock for commitment shares under Standby Equity Purchase Agreement	62		62
Net and comprehensive loss	(24,856)			(24,030)	(826)
Ending balance (in shares) at Mar. 31, 2022		163,253,000
Ending balance at Mar. 31, 2022	$ 150,570	$ 16	179,884	(28,123)	(1,207)
Beginning balance (in shares) at Dec. 31, 2022	168,817,000	168,817,000
Beginning balance at Dec. 31, 2022	$ 112,075	$ 17	190,215	(77,418)	(739)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)	1,647,000	2,000
Stock based compensation expense	$ 1,987		1,987
Issuance of common stock for vesting of restricted stock units (in shares)		1,591,000
Shares withheld related to net share settlement of stock-based awards (in shares)		(581,000)
Shares withheld related to net share settlement of stock-based awards	(382)		(382)
Net and comprehensive loss	$ (23,929)			(24,331)	402
Ending balance (in shares) at Mar. 31, 2023	169,829,000	169,829,000
Ending balance at Mar. 31, 2023	$ 89,751	$ 17	$ 191,820	$ (101,749)	$ (337)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
OPERATING ACTIVITIES:
Net loss	$ (24,331,000)	$ (24,030,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,000,000	268,000
Amortization of right-of-use assets	383,000	355,000
Amortization of debt discounts and issuance costs	1,798,000	0
Amortization of insurance premiums	1,218,000	0
Inventory reserves	(471,000)	1,064,000
Impairment of assets held for sale	1,039,000	0
Change in fair value of derivative instruments	97,000	435,000
Change in fair value of earn-out shares liability	52,000	(2,624,000)
Net realized losses on marketable debt securities, available-for-sale	91,000	6,000
Stock-based compensation expense	2,012,000	1,391,000
Other non-cash items	(475,000)	732,000
Changes in operating assets and liabilities:
Accounts receivable	1,268,000	(3,495,000)
Inventories	1,064,000	(7,910,000)
Prepaid expenses and other current assets	(1,791,000)	1,914,000
Other assets	(222,000)	0
Accounts payable	635,000	(2,620,000)
Other liabilities	1,307,000	3,210,000
Net cash used in operating activities	(15,326,000)	(31,304,000)
INVESTING ACTIVITIES:
Purchase of property and equipment	(253,000)	(2,998,000)
Proceeds from sales and maturities of marketable debt securities, available-for-sale	23,065,000	30,151,000
Net cash provided by investing activities	22,812,000	27,153,000
FINANCING ACTIVITIES:
Principal payment of equipment leases	(600,000)	(83,000)
Proceeds from short-term insurance financing note	2,187,000	0
Payment for short-term insurance financing note	(1,427,000)	0
Payments of convertible notes and prepayment premiums	(9,450,000)	0
Taxes paid related to net share settlement of stock-based awards	(382,000)	(98,000)
Net cash used in financing activities	(9,672,000)	(181,000)
Net decrease in cash, cash equivalents and restricted cash	(2,186,000)	(4,332,000)
Cash, cash equivalents and restricted cash, beginning of period	38,675,000	19,176,000
Cash, cash equivalents and restricted cash, end of period	36,489,000	14,844,000
Reconciliation of Cash, Cash Equivalents and Restricted Cash to Condensed Consolidated Balance Sheets:
Cash and cash equivalents	36,489,000	11,810,000
Restricted cash	0	3,034,000
Total cash, cash equivalents and restricted cash	36,489,000	14,844,000
Supplemental disclosure of cash flow information
Cash paid for interest	980,000	0
Supplemental disclosure of non-cash investing and financing activities
Purchase of property and equipment in accounts payable	2,000	97,000
Recognition of right-of-use asset and lease liabilities upon ASC 842 adoption on 1/1/2022	0	7,682,000
ROU assets obtained in exchange for operating lease obligations	$ 0	$ 437,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Change in net unrealized loss, tax	$ 0	$ 0

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Xos, Inc. and its wholly owned subsidiaries (collectively, the “Company” or “Xos”) is a leading fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Class 5-8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions™ to support electric vehicle fleets. The Company’s proprietary fleet management software, Xosphere™, integrates vehicle operation and vehicle charging to provide commercial fleet operators a more seamless and cost-efficient vehicle ownership experience than traditional internal combustion engine counterparts. Xos developed the X-Platform (its proprietary, purpose-built vehicle chassis platform) and the X-Pack (its proprietary battery system) specifically for the medium- and heavy-duty commercial vehicle segment with a focus on last-mile commercial fleet operations. Xos’ “Fleet-as-a-Service” package offers customers a comprehensive suite of commercial products and services facilitate electric fleet operations and seamlessly transition their traditional combustion-engine fleets to battery-electric vehicles. Business Combination Xos, Inc. was initially incorporated on July 29, 2020 as a Cayman Islands exempted company under the name “NextGen Acquisition Corporation” (“NextGen”). On August 20, 2021, the transactions contemplated by the Agreement and Plan of Merger, as amended on May 14, 2021, by and among NextGen, Sky Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of NextGen (“Merger Sub”), and Xos, Inc., a Delaware corporation (now known as Xos Fleet, Inc., “Legacy Xos”), were consummated (the “Closing”), whereby Merger Sub merged with and into Legacy Xos, the separate corporate existence of Merger Sub ceased and Legacy Xos became the surviving corporation and a wholly owned subsidiary of NextGen (such transaction the “Merger” and, collectively with the Domestication, the “Business Combination”). As a result, Xos became the publicly traded entity listed on the Nasdaq Global Market. Risks and Uncertainties In recent years, the United States and other significant markets have experienced high volatility and uncertainty in the capital markets, including inflation. interest rate increases, recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, supply chain disruption and geopolitical events, such as the war between Russia and Ukraine. These conditions could make it difficult for our customers and us to accurately forecast and plan future business activities, and could cause our customers to slow spending on our products and services or impact their ability to make timely payments. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. In addition, there is a risk that our current or future suppliers, service providers, manufacturers or other partners may not survive such difficult economic times, which would directly affect our ability to attain our operating goals on schedule and on budget. The ultimate impact of current economic conditions on the Company is uncertain, but it may have a material negative impact on the Company’s business, operating results, cash flows, liquidity and financial condition. COVID-19 and actions taken to mitigate its spread have had and may continue to have an adverse impact on the economies and financial markets of many countries, including the areas in which the Company operates. There are no comparable recent events which may provide guidance, and, as a result, the ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. As a result, the Company is unable to predict the cumulative impact, both in terms of severity and duration, that the COVID-19 pandemic will have on its business, operating results, cash flows, liquidity and financial condition. Additionally, ongoing geopolitical events, such as the military conflict between Russia and Ukraine and related sanctions, may increase the severity of supply chain disruptions and further hinder our ability to source inventory for our vehicles. The conflict continues to evolve and its ultimate impact on the Company is uncertain, but a prolonged conflict may have a material negative impact on the Company’s business, operating results, cash flows, liquidity and financial condition. Although the Company has used the best current information available to it in its estimates, actual results could materially differ from the estimates and assumptions developed by management. Liquidity As an early stage growth company, the net losses and cash outflows the Company has incurred since inception are consistent with its strategy and budget. The Company will continue to incur net losses and cash outflows in accordance with its operating plan as the Company continues to expand its research and development activities with respect to its vehicles and battery systems, scale its operations to meet anticipated demand and establish its Fleet-as-a-Service offering. As a result, the Company strives to maintain robust access to capital in order to fund and scale its operations. The Company may raise additional capital through a combination of debt financing, other non-dilutive financing and/or equity financing, including through asset-based lending and/or receivable financing. The Company’s ability to access capital when needed is not assured and, if capital is not available to the Company when and in the amounts needed, the Company could be required to delay, scale back or abandon some or all of its development programs and other operations, which could materially harm its business, prospects, financial condition and operating results. Global economic conditions have been worsening, with disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the effects of COVID-19, recessions, rising inflation rates, including the recent and potential bank failures, supply chain disruption, fuel prices, international currency fluctuations, and geopolitical events such as local and national elections, corruption, political instability and acts of war or military conflict including repercussions of the war between Russia and Ukraine, or terrorism. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its commercialization, research and development programs and/or other efforts. In August 2021, the Company consummated the Business Combination, which resulted in net cash proceeds of approximately $216.7 million. In December 2020, the Company had the initial closing of its Series A Financing, and in the first quarter of 2021, the Company completed the Series A Financing, including the conversion of all its convertible notes into shares of Legacy Xos preferred stock. As of March 31, 2023, the Company’s principal sources of liquidity were its cash and cash equivalents and investments in marketable debt securities, available-for-sale aggregating to $64.0 million. The Company’s short-term uses of cash are for working capital and to pay interest on its debt and its long-term uses of cash are for working capital and to pay the principal of its indebtedness. The Company believes that its existing cash resources are sufficient to support planned operations for the next 12 months, and the Company has a base of assets against which it expects to be able to borrow in the future. The Company believes it will meet longer-term expected future cash requirements and obligations through a combination of cash flows from operating activities, available cash balances, and advances under the Standby Equity Purchase Agreement (the "SEPA"). In addition, the Company may seek to raise additional capital through debt financing through asset-based lending and/or receivable financing or through the sale of equity or debt securities. Supply Chain Disruptions The Company’s ability to source certain critical inventory items has been impacted by negative global economic conditions caused by factors such as the COVID-19 pandemic, and may continue to be impacted in the future. The Company continues to face widespread shortages for specific components, such as semiconductor chips and battery cells, and disruptions to the supply of components due to port congestion and fluctuating fuel prices. Despite these disruptions, the Company has taken significant measures to source inventory for its vehicles and its supply chain team has been working with vendors to find alternative solutions to overcome these constraints and where appropriate, working to find alternate sources of supply for critical components, including placing orders in advance of projected need to ensure inventory is able to be delivered in time for production plans.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies The following is a summary of the significant accounting policies consistently applied in the preparation of the accompanying unaudited condensed consolidated financial statements: Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. They do not include all of the information and footnotes required by U.S. GAAP for complete audited financial statements. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Legacy Xos and Xos Services. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (primarily consisting of normal accruals) considered for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the years ended December 31, 2022 and 2021 presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenues and expenses during the reporting periods. The areas with significant estimates and judgments include, among others, inventory valuation, incremental borrowing rates for assessing operating and financing lease liabilities, useful lives of property and equipment, contingent earn-out shares liability, stock-based compensation, valuation of convertible debt and related embedded derivatives, common stock warrant liability and product warranty liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements. Accounts Receivable, Net The Company records unsecured and non-interest bearing accounts receivable at the gross invoice amount, net of any allowance for expected credit losses. The Company maintains its allo wance for expected credit losses at a level considered adequate to provide for potential account losses on the balance based on management’s evaluation of past losses, current customer conditions, and the anticipated impact of current economic conditions. The Company recorded an allowance for expected credit losses of $39,000 as of March 31, 2023. No allowance for doubtful accounts was recorded as of March 31, 2022. Investments in Marketable Debt Securities, Available-for-Sale The Company maintains a portfolio of investments in a variety of fixed and variable rate debt securities, including U.S. treasuries, corporate debt, asset-backed securities and other, non-U.S. government and supranational bonds and certificate of deposit. The Company considers its investments in marketable debt securities to be available-for-sale, and accordingly, are recorded at their fair values. The Company determines the appropriate classification of investments in marketable debt securities at the ti me of purchase. Unrealized gains and losses on marketable debt securities, available-for-sale are recorded in Accumulated other comprehensive loss which is included within stockholders’ equity. Interest along with amortization of purchase premiums and accretion of discounts from the purchase date through the estimated maturity date, including consideration of variable maturities and contractual call provisions, are included in other income (expenses), net in the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses on the sale of marketable debt securities, available-for-sale are recorded in Other (expense) income, net. The Company typically invests in highly-rated debt securities, and its investment policy generally limits the amount of credit exposure to any one issuer. The policy requires substantially all investments to be investment grade, with the primary objective of minimizing the potential risk of principal loss. See Note 8 — Investments for additional information. On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments — Credit Losses which requires that credit losses be presented as an allowance rather than as an impairment write-down. Adoption of the standard had no material impact on its financial statements. The Company reviews quarterly its investment portfolio of all securities in an unrealized loss position to determine if an impairment charge or credit reserve is required. The Company excludes accrued interest from both the fair value and the amortized cost basis of marketable debt securities, available-for-sale, for the purposes of identifying and measuring an impairment. An investment is impaired if the fair value is less than its amortized cost basis. Impairment relating to credit losses is recorded through a reduction in the amortized cost of the security or an allowance for credit losses and credit loss expense (included in selling, general and administrative expense), limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded as a credit loss is recorded through other comprehensive income (loss), net of applicable taxes. The Company made an accounting policy election to not measure an allowance for credit losses for accrued interest receivables. The Company evaluates write-off of accrued interest receivable at the time credit loss exists for the underlying security. As of March 31, 2023 and 2022, we did not recognize any allowance for expected credit losses or impairment, respectively, on marketable debt securities - available-for-sale. Warranty Liability The Company provides customers with a product warranty that assures that the products meet standard specifications and are free for periods typically between 2 to 5 years. The Company accrues warranty reserve for the products sold, which includes its best estimate of the projected costs to repair or replace items under warranties and recalls if identified. These estimates are based on actual claims incurred to date and an estimate of the nature, frequency and costs of future claims. These estimates are inherently uncertain given the Company’s relatively short history of sales, and changes to its historical or projected warranty experience may cause material changes to the warranty reserve in the future. Claims incurred under the Company’s standard product warranty programs are recorded based on open claims. The Company recorded warranty liability within other current liabilities in the consolidated balance sheets as of March 31, 2023 and December 31, 2022. The reconciliation of the change in the Company’s product liability balances consisted of the following (in thousands) : March 31, 2023 March 31, 2022 Warranty liability, beginning of period $ 1,099 $ 177 Reduction in liability (payments) (216) — Increase in liability 272 298 Warranty liability, end of period $ 1,155 $ 475 Concentrations of Credit and Business Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of March 31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. During the three months ended March 31, 2023, one customer accounted for 82% of the Company’s revenues (gross of customer returns) . During the three months ended March 31, 2022, three customers accounted for 24%, 11%, and 10% of the Company’s revenues . As of March 31, 2023, two customers accounted for 59% and 15% of the Company’s accounts receivable. As of March 31, 2023, four customers accounted for 13%, 11%, 11%, and 11% of the Company’s accounts receivable. Concentration of Supply Risk The Company is dependent on its suppliers, the majority of which are single-source suppliers, and the inability of these suppliers to deliver necessary components of its products according to the schedule and at prices, quality levels and volumes acceptable to the Company, or its inability to efficiently manage these components, could have a material adverse effect on the Company’s results of operations and financial condition. Recent Accounting Pronouncements Issued and Adopted: The Company adopted ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), as amended, on January 1, 2023 using the modified retrospective approach method. As of March 31, 2023 and December 31, 2022 the Company had $27.5 million and $50.6 million, respectively, in marketable debt securities, available for sale which are subject to the new standard. As of January 1, 2023 and March 31, 2023, these marketable debt securities, available for sale have an average credit rating of A and no allowance for expected credit losses has been recorded. Under the modified retrospective approach, the Company would record a cumulative effect adjustment to retained earnings by recording an initial allowance for credit losses on marketable debt securities, available-for sale. Periods presented that are prior to the adoption date of January 1, 2023 will not be adjusted. ASU 2016-13 replaced the incurred loss impairment model with a methodology that reflects a current expected credit loss and made targeted changes to the impairment model for available-for-sale debt securities. ASU 2016-13 impacted all of the Company’s investments held at fair value, which included its marketable debt securities, available for sale. Upon adoption of ASU 2016-13 on January 1, 2023, no adjustment was recorded by the Company for an initial allowance for credit losses on marketable debt securities, available for sale and there was no cumulative effect adjustment to retained earnings. Subsequent increases or decreases in the allowance for credit losses on marketable debt securities, available for sale will be recorded in the Company's condensed consolidated statements of operations and comprehensive loss.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregated revenues by major source for the three months ended March 31, 2023 and 2022 consisted of the following ( in thousands ): Three Months Ended March 31, 2023 2022 Product and service revenue Stepvans & vehicle incentives (1) $ 4,262 $ 6,863 Powertrains 5 14 Fleet-as-a-Service 166 95 Total product and service revenue 4,433 6,972 Ancillary revenue 264 59 Total revenues $ 4,697 $ 7,031

Inventories

Inventories	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories Inventory amounted to $57.0 million and $57.5 million as of March 31, 2023 and December 31, 2022, respectively, and consisted of the following (in thousands) : March 31, 2023 December 31, 2022 Raw materials $ 39,412 $ 40,271 Work in process 3,213 4,618 Finished goods 14,382 12,651 Total inventories $ 57,007 $ 57,540 Inventories as of March 31, 2023 and December 31, 2022 was comprised of raw materials, work in progress related to the production of vehicles for sale and finished goods inventory including vehicles in transit to fulfill customer orders, new vehicles and Energy Services products available for sale and new vehicles awaiting final pre-delivery quality review inspection.

Selected Balance Sheet Data

Selected Balance Sheet Data	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Selected Balance Sheet Data	Selected Balance Sheet Data Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets as of March 31, 2023 and December 31, 2022 consisted of the following ( in thousands ): March 31, 2023 December 31, 2022 Prepaid inventories $ 2,263 $ 2,372 Prepaid expenses and other (1) 1,295 1,299 Contract assets 1,132 290 Financed insurance premiums 3,036 2,289 Assets held for sale 750 1,850 Total prepaid expenses and other current assets $ 8,476 $ 8,100 ____________ (1) Primarily relates to prepaid insurance, licenses, subscriptions, contract assets and other receivables. Other Current Liabilities Other current liabilities as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 December 31, 2022 Accrued expenses and other (1) $ 7,232 $ 7,589 Contract liabilities 764 193 Customer deposits 1,194 721 Warranty liability 1,155 1,099 Equipment notes payable 314 303 Short-term insurance financing notes 2,824 2,065 Operating lease liabilities, current 1,557 1,530 Finance lease liabilities, current 2,128 2,116 Total other current liabilities $ 17,168 $ 15,616 ____________ (1) Primarily relates to accrued inventory purchases, personnel costs, wages, health benefits, vacation and other accruals. Revenue recognized from the customer deposits balance as of December 31, 2022 was $0.2 million for the three months ended March 31, 2023. Other Non-Current Liabilities Other non-current liabilities as of March 31, 2023 and December 31, 2022 consisted of the following ( in thousands ) March 31, 2023 December 31, 2022 Accrued interest expense $ 1,277 $ 784 Equipment notes payable, non-current 860 942 Operating lease liabilities, non-current 4,770 5,174 Finance lease liabilities, non-current 3,560 4,100 Total other non-current liabilities $ 10,467 $ 11,000

Earn-out Shares Liability

Earn-out Shares Liability	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Earn-out Shares Liability	Earn-out Shares Liability The Company has a contingent obligation to issue 16.2 million shares (the “Earn-out Shares”) of Common Stock and grant 261,000 restricted stock units (“Earn-out RSUs”) to certain stockholders and employees upon the achievement of certain market share price milestones within specified periods following the Business Combination on August 20, 2021. The Earn-out Shares will be issued in tranches based on the following conditions: i. If the volume-weighted average closing share price (“VWAP”) of the Common Stock equals or exceeds $14.00 per share for any 10 trading days within any consecutive 20-trading day period between the merger closing date and the five year anniversary of such closing date (“Earn-out Period”), then the Company is required to issue an aggregate of 5.4 million shares (“Tranche 1 Earn-out Shares”) of Common Stock to holders with the contingent right to receive Earn-out Shares (excluding any Earn-out RSUs). If after Closing and during the Earn-out Period, there is a Change in Control (as defined in the Merger Agreement), the Company is required to issue Tranche 1 Earn-out Shares when the value per share of the Company is equal to or greater than $14.00 per share, but less than $20.00. If there is a change in control where the value per share of commons stock is less than $14.00, then the Earn-out Shares shall terminate prior to the end of the Earn-out Period and no common stock shall be issuable. ii. If the VWAP of the Common Stock equals or exceeds $20.00 per share for any 10 trading days within any consecutive 20-trading day period during the Earn-out Period, then the Company is required to issue an aggregate of 5.4 million shares (“Tranche 2 Earn-out Shares”) of Common Stock to holders with the contingent right to receive Earn-out Shares (excluding any Earn-out RSUs). If after Closing and during the Earn-out Period, there is a Change in Control (as defined in the Merger Agreement), the Company is required to issue Tranche 2 Earn-out Shares when the value per share of the Company is equal to or greater than $20.00 per share, but less than $25.00. iii. If the VWAP of the Common Stock equals or exceeds $25.00 per share for any 10 trading days within any consecutive 20-trading day period during the Earn-out Period, then the Company is required to issue an aggregate of 5.4 million shares (“Tranche 3 Earn-out Shares”) of Common Stock to holders with the contingent right to receive Earn-out Shares (excluding any Earn-out RSUs). If after Closing and during the Earn-out Period, there is a Change in Control (as defined in the Merger Agreement), the Company is required to issue Tranche 3 Earn-out Shares when the valuer per share of the Company is equal to or greater than $25.00 per share. Pursuant to the guidance under ASC 815, Derivatives and Hedging, the right to Earn-out Shares was classified as a Level 3 fair value measurement liability, and the increase or decrease in the fair value during the reporting period is recognized in the condensed consolidated statement of operations accordingly. The fair value of the Earn-out Shares liability was estimated using the Monte Carlo simulation of the stock prices based on historical and implied market volatility of a peer group of public companies. As of March 31, 2023 and December 31, 2022, the fair value of the Earn-out Shares liability was estimated to be $0.6 million and $0.6 million, respectively. The Company recognized a loss on the change in fair value in Earn-out Shares liability of $52,000 and gain of $2.6 million in its consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, respectively. The allocated fair value to the Earn-out RSU component, which is covered by ASU 718, Compensation — Stock Compensation, is recognized as stock-based compensation expense over the vesting period commencing on the grant date of the award.

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Convertible Notes	Convertible Notes Convertible Debentures On August 9, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with YA II PN, Ltd. (“Yorkville”) for the issuance of convertible debentures, convertible into shares of Common Stock subject to certain conditions and limitations, in the principal amount of up to $35 million (the “Convertible Debentures”). On August 11, 2022, pursuant to the Securities Purchase Agreement, the Company sold and issued a Convertible Debenture to Yorkville in the principal amount of $20.0 million. On September 21, 2022, pursuant to the Securities Purchase Agreement, the Company sold and issued an additional Convertible Debenture to Yorkville in the principal amount of $15.0 million. Yorkville will use commercially reasonable efforts to convert $2.0 million during each 30-day period beginning on September 9, 2022, provided that certain conditions are satisfied as of each such period. The Convertible Debentures bear interest at an annual rate of 6%, payable at maturity, and have a maturity date of November 11, 2023, which the Company may extend by an additional three months in certain instances. The interest rate will increase to an annual rate of (i) 10% upon the occurrence and during the continuance of an event of default, and (ii) 7.5% for so long as “Registration Event” (as defined in the Convertible Debentures) remains in effect in accordance with the Registration Rights Agreement (described below). The Convertible Debentures provide a conversion right, in which any portion of the principal amount of the debt, together with any accrued but unpaid interest, may be converted into the Common Stock at a conversion price equal to the lower of (i) $2.4733 or (ii) 97% of the lowest daily volume weighted average price (“VWAP”) of the Common Stock during the three consecutive trading days immediately preceding the conversion (but not lower than a certain floor price (“Floor Price”) that is subject to further adjustment in accordance with the terms of the Convertible Debentures). The Floor Price was $0.59 as of March 31, 2023. The Convertible Debentures may not be converted into shares of Common Stock to the extent such conversion would result in Yorkville and its affiliates having beneficial ownership of more than 9.99% of the then outstanding shares of Common Stock; provided that this limitation may be waived by the investor upon not less than 65 days’ prior notice to the Company. The Convertible Debentures provide the Company, subject to certain conditions, with a redemption right pursuant to which the Company, upon 10 business days’ prior notice to Yorkville, may redeem, in whole or in part, any of the outstanding principal and interest thereon at a redemption price equal to (i) the principal amount being redeemed, (ii) all accrued and unpaid interest under the applicable Convertible Debenture, and (iii) a redemption premium of 5% of the principal amount being redeemed. The Convertible Debentures include a monthly prepayment provision that is triggered if (i) the daily VWAP of the Company’s Common Stock is less than the Floor Price for 5 consecutive trading days or (ii) the Company has issued pursuant to the Convertible Debentures in excess of 95% of the Common Stock available under the Exchange Cap, as defined in the Convertible Debentures. If this provision is triggered, the Company is required to make monthly payments, beginning on the 10th calendar day after the triggering date, of up to $4.0 million of principal (subject to a redemption premium of 5%) plus accrued and unpaid interest, subject to certain conditions (“Prepayments”). The monthly Prepayment requirement will cease if (i) the Company provides Yorkville a reset notice reducing the Floor Price, limited to no more than 85% of closing price on the trading day immediately prior to the notice and not less than $0.50 or (ii) the daily VWAP is greater than the Floor Price for 3 consecutive trading days. In the event the monthly Prepayment provision was triggered by the issuance in excess of 95% of the Common Stock available under the Exchange Cap, the monthly Prepayment requirement will cease on the date the Company has obtained stockholder approval to increase the number of shares of Common Stock available under the Exchange Cap and/or the Exchange Cap no longer applies. The monthly Prepayment requirement will cease upon the payment in full of all obligations under the Convertible Debentures. Three Prepayments, which included $9.0 million of principal payments, $0.5 million payment of redemption premiums and $1.0 million payment of accrued interest, were made during the three months ended March 31, 2023. The Company and Yorkville entered into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which the Company is required to file a registration statement registering the resale by Yorkville of any shares of the Company’s Common Stock issuable upon conversion of the Convertible Debentures. The Company filed the registration statement on September 8, 2022 and received notice of effectiveness on September 19, 2022. The derivative features of the Convertible Debentures are carried on the Company’s consolidated balance sheet at fair value of $0.5 million and $0.4 million in Derivative liabilities as of March 31, 2023 and December 31, 2022, respectively. For the three months ended March 31, 2023, the Company recorded a loss on the change in fair value of derivative liabilities of $0.1 million. The derivative liabilities associated with the Convertible Debentures will remain in effect until such time as the underlying convertible notes are exercised or terminated (see Note 1 0 — Derivative Instruments ). The Company classified the Convertible Debentures and associated derivative liabilities as current liabilities given a maturity date of less than one year. The Company received proceeds, net of a 2% original issuance discount, of $34.3 million from Yorkville. Debt issuance costs of $0.3 million were recorded at inception of the Convertible Debentures. Debt discount and issuance costs are amortized through the maturity date of the debenture using the effective interest rate method. The Convertible Debentures will not be included in the computation of either basic or diluted EPS for the three months ended March 31, 2023 in Note 16 — Net Loss per Share . This financial instrument is not included in basic EPS because it does not represent participating securities. Further, the Convertible Debentures are not included in diluted EPS because the Company reported a net loss from continuing operations for the three months ended March 31, 2023; thus, including these financial instruments would have an antidilutive effect on EPS. As of March 31, 2023 and December 31, 2022, the Company had a principal balance of $24.0 million outstanding, net of unamortized debt discounts and issuance costs of $4.4 million and $33.0 million outstanding, net of unamortized debt discounts and issuance costs of $6.2 million, respectively. Amortization of debt discounts and issuance costs, recorded in other income (expense), net, for the three months ended March 31, 2023 totaled $1.8 million. The Company recorded interest expense of $0.4 million in other income (expense), net related to the Convertible Debentures during the three months ended March 31, 2023. Convertible Promissory Note On August 9, 2022, the Company entered into a note purchase agreement (the “Note Purchase Agreement”) with Aljomaih Automotive Co. (“Aljomaih”) under which the Company agreed to sell and issue to Aljomaih a convertible promissory note with a principal amount of $20.0 million. On August 11, 2022, pursuant to the Note Purchase Agreement, the Company sold and issued $20.0 million in principal amount of a convertible promissory note (the “Original Note”) to Aljomaih. On September 28, 2022, the Company and Aljomaih agreed to amend and restate the Original Note (as amended and restated, the “Note”) to, among other things, adjust the calculation of the shares of the Company’s Common Stock issuable as interest, as described further below. The Note bears interest at a rate of 10.0% per annum, payable at maturity in validly issued, fully paid and non-assessable shares of Common Stock (“Interest Shares”), unless earlier converted or paid. The Note matures on August 11, 2025. If the 10-day VWAP ending on the trading day immediately prior to the applicable payment date is greater than or equal to the Nasdaq Minimum Price (as defined in the Note) or the Company has received the requisite approval from its stockholders, the number of Interest Shares to be issued will be calculated based on the 10-day; otherwise, the number of Interest Shares to be issued will be based on the Nasdaq Minimum Price. The conversion price for the Note will initially be equal to $2.3817 per share, subject to adjustment in some events pursuant to the terms of the Note. The Company will have the right, in its sole discretion and exercisable at its election by sending notice of such exercise to Aljomaih, to irrevocably fix the method of settlement that will apply to all conversions of Notes. Methods of settlement include (i) physical settlement in shares of Common Stock, (ii) cash settlement determined by multiplying the principal being converted by the 10-day VWAP ending on the trading day immediately prior to the conversion date and dividing by the conversion price, or (iii) a combination of Common Stock and cash. The Note may not be converted into shares of Common Stock and Interest Shares may not be issued to the extent (i) such conversion or issuance would result in the investor having beneficial ownership of more than 19.99% of the then outstanding shares of the Company’s Common Stock or (ii) the aggregate number of shares issued would exceed the Authorized Share Cap (as defined in the Note). The Note also includes an optional redemption feature that provides the Company, on or after August 11, 2024, or as otherwise agreed to between the Company and Aljomaih in writing, the right to redeem the outstanding principal and accrued and unpaid interest, upon written notice not less than 5 trading days prior to exercise of the option, in full or in part and without penalty. The Company accounts for the Note in accordance with the guidance contained in ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, under which the Note was analyzed for the identification of material embedded features that meet the criteria for equity treatment and/or bifurcation and must be recorded as a liability. The Company classified the Note as a non-current liability given a maturity date of greater than one year. The Company received proceeds of $20.0 million from Aljomaih. Debt issuance costs of $0.1 million were recorded at inception of the Note. Debt issuance costs are amortized through the maturity date of the Note using the effective interest rate method. The Note will not be included in the co mputation of either basic or diluted EPS for the three months ended March 31, 2023 in Note 16 - Net Loss per Share . This f inancial instrument is not included in basic EPS because it does not represent participating securities. Further, the Note is not included in diluted EPS because the Company reported a net loss from continuing operations for the three months ended March 31, 2023; thus, including these financial instruments would have an antidilutive effect on EPS. As of March 31, 2023 and December 31, 2022, the Company had a principal balance of $20.0 million outstanding, net of unamortized debt and issuance costs of $0.1 million and $20.0 million outstanding, net of unamortized debt and issuance costs $0.1 million, respectively. Amortization of debt issuance costs, recorded in other income (expense), net, for the three months ended March 31, 2023 was immaterial. The Company recorded interest expense of $0.5 million in other income (expense), net related to the Note during the three months ended March 31, 2023.

Investments

Investments	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Amortized cost, gross unrealized gains/losses in accumulated other comprehensive loss and fair value of marketable debt securities, available-for-sale, by type of security as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: Corporate debt security $ 24,185 $ — $ (303) $ 23,882 U.S. treasuries 651 — (1) 650 Asset-backed security and other 3,029 — (33) 2,996 $ 27,865 $ — $ (337) $ 27,528 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: Corporate debt security $ 40,177 $ — $ (612) $ 39,565 U.S. treasuries 2,201 — (21) 2,180 Asset-backed security and other 5,324 — (76) 5,248 Non-U.S. government and supranational bonds 3,685 — (30) 3,655 $ 51,387 $ — $ (739) $ 50,648 As of March 31, 2023, no allowance for credit losses was recorded related to an impairment of available-for-sale securities. The Company’s investments in marketable debt securities, available-for-sale that have been in a continuous unrealized loss position by type of security as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt security $ 405 $ — $ 23,477 $ (303) $ 23,882 $ (303) U.S. treasuries — — 650 (1) 650 (1) Asset-backed security and other — — 2,996 (33) 2,996 (33) $ 405 $ — $ 27,123 $ (337) $ 27,528 $ (337) December 31, 2022 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt security $ 1,790 $ (2) $ 37,775 $ (610) $ 39,565 $ (612) U.S. treasuries — — 2,180 (21) 2,180 (21) Asset-backed security and other — — 5,248 (76) 5,248 (76) Non-U.S. government and supranational bonds — — 3,655 (30) 3,655 (30) $ 1,790 $ (2) $ 48,858 $ (737) $ 50,648 $ (739) Gross realized gains and gross realized losses from the sales of the Company’s marketable debt securities, available-for-sale for the three months ended March 31, 2023 and 2022 consisted of the following (in thousands) : Three Months Ended March 31, 2023 2022 Gross realized gains $ — $ — Gross realized losses $ (91) $ (6) Amortized cost and fair value of marketable debt securities, available-for-sale by contractual maturity as of March 31, 2023 consisted of the following ( in thousands , except weighted average data): Amortized Cost Fair Value Due in one year or less $ 27,865 $ 27,528 Weighted average contractual maturity 0.3 years Amortized cost and fair value of marketable debt securities, available-for-sale by contractual maturity as of December 31, 2022 consisted of the following ( in thousands , except weighted average data): Amortized Cost Fair Value Due in one year or less $ 51,387 $ 50,648 Weighted average contractual maturity 0.3 years Actual maturities may differ from contractual maturities because certain issuers may have the right or obligation to prepay certain obligations with or without penalties.

Equity

Equity	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note And Temporary Equity [Abstract]
Equity	Equity Xos Common and Preferred Stock The Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Company is authorized to issue is 1,010,000,000 shares. 1,000,000,000 shares shall be Common Stock, each having a par value of one-hundredth of one cent ($0.0001). 10,000,000 shares shall be Preferred Stock, each having a par value of one-hundredth of one cent ($0.0001). Voting Rights : Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Company for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock). Preferred Stock : The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the “Board of Directors”) is hereby expressly authorized to provide for the issue of all or any number of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series subsequent to the issuance of shares of that series. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. Nasdaq Deficiency Letter: On December 28, 2022, the Company received a deficiency letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days prior to the date of the Letter, the closing bid price for the Common Stock, was below $1.00 per share, which is the minimum closing bid price required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (“Rule 5450(a)(1)”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a grace period of 180 calendar days, or until June 26, 2023, to meet the minimum bid price requirement of Rule 5450(a)(1) under the listing rules of Nasdaq. If at any time during the 180-calendar day grace period, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of ten consecutive business days (unless the Nasdaq staff exercises its discretion to extend this ten business day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H)), Nasdaq will provide the Company written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance within the 180-calendar day grace period, the Company may be eligible for an additional 180-calendar day grace period if it applies to transfer the listing of the Common Stock to the Nasdaq Capital Market. To qualify, the Company must meet the continued listing requirement for the applicable market value of publicly held shares requirement and all other applicable initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, based on the Company’s most recent public filings and market information and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Company would have the right to appeal a determination to delist the Common Stock, and the Common Stock would remain listed on the Nasdaq Global Market until the completion of the appeal process. Standby Equity Purchase Agreement On March 23, 2022, the Company entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd. (“Yorkville”), whereby the Company has the right, but not the obligation, to sell to Yorkville up to $125.0 million of shares of its Common Stock at its request any time during the 36 months following the execution of the SEPA, subject to certain conditions. The Company expects to use any net proceeds for working capital and general corporate purposes. As consideration for Yorkville’s commitment to purchase shares of common stock at the Company’s direction upon the terms and subject to the conditions set forth in the purchase agreement, upon execution of the purchase agreement, the Company issued 18,582 shares of common stock to Yorkville. Under the Securities Purchase Agreement, the Company agreed not to effect an advance under the SEPA, without the advance mutual consent of both the Company and Yorkville, until the earliest of the date (i) all Convertible Debentures have been repaid or converted into Common Stock or (ii) Yorkville no longer has any right or ability to convert any portion of the Convertible Debentures into Common Stock (collectively, the “Consent Termination Date”). Yorkville agreed to extend the term set forth in the SEPA for a number of days equal to the number of days between the date of the Securities Purchase Agreement and the Consent Termination Date. As of March 31, 2023 and December 31, 2022, the remaining commitment available under the agreement was $120.7 million.

Derivative Instruments

Derivative Instruments	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative Instruments Public and Private Placement Warrants As of March 31, 2023, the Company had 18,633,301 Public Warrants and 199,997 Private Placement Warrants outstanding, with fair values of $0.7 million and $7,000, respectively. The Public Warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire on August 20, 2026 or earlier upon redemption or liquidation. The Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the units and only whole Public Warrants will trade. The Public Warrants became exercisable; provided that the Company has an effective registration statement under the Securities Act covering the issuance of the Common Stock issuable upon exercise of the Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permits holders to exercise their Warrants on a cashless basis under the circumstances specified in the warrant agreement). A registration statement was filed with the SEC covering the issuance of the Common Stock issuable upon exercise of the Warrants, and the Company will use its commercially reasonable efforts to maintain the effectiveness of such registration statement and a current prospectus relating to those shares of Common Stock until the Public Warrants expire or are redeemed. If the shares of Common Stock are at the time of any exercise of a Public Warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, requires holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the Common Stock issuable upon exercise of the Private Placement Warrants were not transferable, assignable or salable until September 19, 2021, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial shareholders or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. Redemption of Warrants for cash when the price per Common Stock equals or exceeds $18.00: Once the Warrants become exercisable, the Company may redeem the outstanding Warrants (except as described above with respect to the Private Placement Warrants): • in whole and not in part; • at a price of $0.01 per Warrant; • upon not less than 30 days’ prior written notice of redemption to each Warrant holder; and • if, and only if, the last reported sale price of Common Stock for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the Warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like). The Company will not redeem the Warrants as described above unless a registration statement under the Securities Act covering the issuance of the Common Stock issuable upon exercise of the Warrants is then effective and a current prospectus relating to those Common Stock is available throughout the 30-day redemption period. If and when the Warrants become redeemable by the Company, it may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of Warrants for Common Stock when the price per share equals or exceeds $10.00: Once the Warrants become exercisable, the Company may redeem the outstanding Warrants (including both Public Warrants and Private Placement Warrants): • in whole and not in part; • at $0.10 per Warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their Warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of Common Stock; • if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and • if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also concurrently be called for redemption on the same terms as the outstanding Public Warrants, as described above. The “fair market value” of Common Stock shall mean the average reported last sale price of Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Warrants. In no event will the Company be required to net cash settle any Warrant. The Warrants may also expire worthless. Embedded Derivative Liabilities on Convertible Debentures The Convertible Debentures are principally debt financial instrument hosts containing various embedded features and options. Upon analysis of these features and options, the Company identified one option present within both Convertible Debentures which required bifurcation from the host debt contract upon issuance of each debenture and subsequent periodic valuation under ASC 815. The Company estimates the fair value of the embedded features using a Monte Carlo simulation (see Note 1 7 — Fair Value Measurements ). The carrying value of the embedded derivatives on the Convertible Debentures were recorded as derivative liabilities on the consolidated balance sheets and changes in fair value are reflected within the consolidated statements of operations and comprehensive loss.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation 2018 Stock Plan On November 27, 2018, the Legacy Xos’ board of directors and stockholders adopted the 2018 Stock Plan. There are no shares available for issuance under the 2018 Stock Plan; however, the 2018 Stock Plan continues to govern the terms and conditions of the outstanding awards granted under the 2018 Stock Plan. Options As of March 31, 2023, there were 1,569,996 Options outstanding under the 2018 Stock Plan. The amount and terms of Option grants were determined by the board of directors of Legacy Xos. The Options granted under the 2018 Stock Plan generally expire within 10 years from the date of grant and generally vest over 4 years, at the rate of 25% on the first anniversary of the date of grant and ratably on a monthly basis over the remaining 36-month period thereafter based on continued service. Stock option activity during the three months ended March 31, 2023 consisted of the following: Options Weighted Average Fair Value Weighted Average Exercise Price Weighted Average Remaining Years Intrinsic Value December 31, 2022 — Options outstanding 1,572,451 $ 0.02 $ 0.02 7.14 $ 670,451 Granted — — — Exercised 1,647 0.02 0.02 Forfeited 808 0.02 0.02 March 31, 2023 — Options outstanding 1,569,996 $ 0.02 $ 0.02 6.90 $ 798,297 March 31, 2023 — Options vested and exercisable 1,105,080 $ 0.02 $ 0.02 6.74 $ 562,066 Aggregate intrinsic value represents the difference between the exercise price of the options and the fair value of the Company’s common stock. The aggregate intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 were approxi mately $800 a nd $1,000, respectively. The Company estimates the fair value of options utilizing the Black-Scholes option pricing model, which is dependent upon several variables, including expected option term, expected volatility of the Company's share price over the expected term, expected risk-free rate and expected dividend yield rate. There were no option grants during the three months ended March 31, 2023 and 2022. 2021 Equity Incentive Plan On August 19, 2021 the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Equity Plan”), which was ratified by the Company’s board of directors on August 20, 2021. The 2021 Equity Plan provides for the grant of incentive stock options (“ISOs”), within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) to employees, including employees of any parent or subsidiary, and for the grant of no statutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, RSUs, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of Xos’ affiliates. As of March 31, 2023, there were 20,701,956 shares of Common Stock available for issuance under the 2021 Equity Plan. RSU activity during the three months ended March 31, 2023 consisted of the following: RSUs Weighted Average Grant Date Fair Value Weighted Average Fair Value December 31, 2022 — RSUs outstanding 10,308,272 $ 1.45 $ 4,565,534 Granted 1,156,455 $ 0.83 $ 969,652 Vested 1,590,991 $ 1.02 $ 1,089,668 Forfeited 650,204 $ 1.21 $ 514,189 March 31, 2023 — RSUs outstanding 9,223,532 $ 1.47 $ 4,842,354 The Company recognized stock-based compensation expense (including earn-out RSUs) in the condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023, and 2022 totaling approximately $2.0 million and $1.4 million, respectively, which consisted of the following ( in thousands) : Three Months Ended March 31, 2023 2022 Cost of goods sold $ 129 $ 29 Research and development 501 261 Sales and marketing 267 58 General and administrative 1,115 1,043 Total stock-based compensation expense $ 2,012 $ 1,391 The unamortized stock-based compensation expense was $12.1 million as of March 31, 2023, and weighted average remaining amortization period as of March 31, 2023 was 2.53 years. The aggregate fair value of RSUs that vested was $1.1 million during the three months ended March 31, 2023.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net consisted of the following at March 31, 2023 and December 31, 2022 (in thousands) : March 31, 2023 December 31, 2022 Equipment $ 7,595 $ 7,595 Finance lease assets 9,283 9,283 Furniture & fixtures 173 173 Company vehicles 1,451 1,389 Leasehold improvements 1,401 1,401 Computers, software and related equipment 3,057 2,865 Construction in progress 347 346 Property and equipment, gross 23,307 23,052 Accumulated depreciation (5,555) (4,471) Property and equipment, net $ 17,752 $ 18,581

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contractual Obligations The Company enters into non-cancellable long-term purchase orders and vendor agreements in the normal course of business. The estimated future payments having a remaining term in excess of one year as of March 31, 2023 were as follows ( in thousands ): Years ended December 31, Minimum Purchase Commitment 2023 (remainder of the year) $ 1,820 2024 1,300 2025 1,300 2026 1,300 2027 1,300 Thereafter 1,300 Total $ 8,320 Legal Contingencies Legal claims may arise from time to time in the normal course of business, the results of which may have a material effect on the Company’s accompanying unaudited condensed consolidated financial statements. As of March 31, 2023 and December 31, 2022, the Company was not a party to any legal proceedings, that individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company’s results of operations, financial condition or cash flows.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company leased property in North Hollywood, California from the Valley Industrial Properties which is owned by the Sunseeker Trust. The Sunseeker Trust is an irrevocable trust with the beneficiary being the mother of the CEO, Dakota Semler. The lease expired during April 2022 and the Company continued to lease the space on a month-to-month basis through December 31, 2022. R ent expense during the three months ended March 31, 2022 amounted to $35,000. The Company has a contract manufacturing agreement with Fitzgerald Manufacturing Partners to provide manufacturing services. The owner of Fitzgerald Manufacturing Partners is a stockholder of the Company. We also have lease agreements with Fitzgerald Manufacturing Partners, for which we recorded rent expense of $0.2 million during each of the three months ended March 31, 2023 and 2022.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate during each of the three months ended March 31, 2023 and 2022 was 0%, respectively. State minimum taxes combined with losses resulted in an effective tax rate below the statutory tax rate of 21% for the three months ended March 31, 2023. The Company recognizes tax benefits related to positions taken, or expected to be taken, on its tax returns only if the positions are "more-likely-than-not" sustainable. Once this threshold has been met, the Company's measurement of its expected tax benefits is recognized in its financial statements. The Company does not have any uncertain tax positions that meet this threshold as of March 31, 2023 and December 31, 2022.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share Basic and diluted net loss per share for the three months ended March 31, 2023 and 2022 consisted of the following ( in thousands , except for per share amounts): Three Months Ended March 31, 2023 2022 Numerator: Net loss $ (24,331) $ (24,030) Net loss attributable to common stockholders, basic (24,331) (24,030) Net loss attributable to common stockholders, diluted (1) $ (24,331) $ (24,030) Denominator: Basic Weighted average shares outstanding, basic 168,829 163,165 Basic net loss per share $ (0.14) $ (0.15) Diluted Weighted average shares outstanding, diluted (1) 168,829 163,165 Diluted net loss per share $ (0.14) $ (0.15) ____________ (1) Net loss attributable to common stockholders, diluted excludes adjustments related to the change in fair value of derivative liabilities, interest expense and amortization of discounts and issuance costs related to Convertible Debentures. Additionally, weighted average shares outstanding, diluted excludes the if-converted shares related to Convertible Debentures. These adjustments were excluded from the calculation of diluted net loss per share as they would have an antidilutive effect (see Note 7 - Convertible Notes ). Potential weighted average shares that were excluded from the computation of diluted net income (loss) per share because their effect was anti-dilutive as of March 31, 2023 and 2022 consisted of the following (in thousands) : March 31, 2023 March 31, 2022 Contingent earn-out shares 16,422 16,422 Common stock public and private warrants 18,833 18,833 Restricted stock units 9,224 731 Stock options 1,570 1,813 Convertible debt 50,518 —

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures , clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. U.S. GAAP establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. As presented in the tables below, this hierarchy consists of three broad levels: • Level 1: Quoted prices in active markets for identical assets and liabilities. • Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; and model-derived valuations whose inputs or significant value drivers are observable. • Level 3: Significant inputs to the valuation model are unobservable and significant to the overall fair value measurement of the assets or liabilities. Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, investments in marketable debt securities, available-for-sale, accounts payable, other current liabilities, Warrants, convertible debt and the associated derivative liability. The fair value of cash and accounts receivable approximates carrying value due to their short-term maturity. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Derivative financial instruments which are required to be measured at fair value on a recurring basis are measured at fair value using Level 3 inputs for all periods presented. Level 3 inputs are unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities carried at fair value on a recurring basis as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 Fair Value Level 1 Level 2 Level 3 Financial assets: Cash and Cash Equivalents (1) : Money market funds $ 30,417 $ 30,417 $ — $ — 30,417 30,417 — — Short-Term Investments: U.S. treasuries 650 650 — — Corporate debt security 23,882 — 23,882 — Asset-backed security and other 2,996 — 2,996 — 27,528 650 26,878 — Total financial assets $ 57,945 $ 31,067 $ 26,878 $ — Financial liabilities: Private Placement Warrants $ 7 $ — $ 7 $ — Public Warrants 659 659 — — Derivative Liabilities 497 — — 497 Contingent Earn-out Shares liability 616 — — 616 Total financial liabilities $ 1,779 $ 659 $ 7 $ 1,113 ____________ (1) Included in total cash and cash equivalents in the condensed consolidated balance sheets. December 31, 2022 Fair Value Level 1 Level 2 Level 3 Financial assets: Cash and Cash Equivalents (1) : Money market funds $ 22,481 $ 22,481 $ — $ — Corporate debt security 2,199 2,199 — — 24,680 24,680 — — Short-Term Investments: U.S. treasuries 2,180 2,180 — — Corporate debt security 39,565 — 39,565 — Asset-backed security and other 5,248 — 5,248 — Non-U.S. government and supranational bonds 3,655 — 3,655 — 50,648 2,180 48,468 — Total financial assets $ 75,328 $ 26,860 $ 48,468 $ — Financial liabilities: Private Placement Warrants $ 7 $ — $ 7 $ — Public Warrants 654 654 — — Derivative Liabilities 405 — — 405 Contingent Earn-out Shares liability 564 — — 564 Total financial liabilities $ 1,630 $ 654 $ 7 $ 969 ____________ (1) Included in total cash and cash equivalents in the condensed consolidated balance sheets. The changes in the fair value of Level 3 financial liabilities during the three months ended March 31, 2023 consisted of the following (in thousands): Derivative Liabilities on Convertible Debentures Contingent Earn-out Shares Liability Fair value at December 31, 2022 $ 405 $ 564 Recognition of earn-out RSUs — — Change in fair value during the period 92 52 Fair value at March 31, 2023 $ 497 $ 616 Significant unobservable inputs related to Level 3 earn-out shares liability consisted of the following: March 31, 2023 December 31, 2022 Stock price $0.53 $0.44 Stock price volatility 80% 80% Expected term 3.39 years 3.64 years Risk-free interest rate 3.8% 4.2% Significant unobservable inputs related to Level 3 derivative liabilities consisted of the following: March 31, 2023 December 31, 2022 Stock price $0.53 $0.44 Stock price volatility 80% 80% Expected term 0.62 years 0.86 years Risk-free interest rate 4.8% 4.6%

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Convertible Debentures Pursuant to the Convertible Debentures, as a result of the daily VWAP being less than the Floor Price for five consecutive trading days, the Company was required to make, and made, a Prepayment to Yorkville in the amount of $3.1 million on May 4, 2023. The Floor Price was $0.59 as of the date of this Report.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Business Combination	Xos, Inc. was initially incorporated on July 29, 2020 as a Cayman Islands exempted company under the name “NextGen Acquisition Corporation” (“NextGen”). On August 20, 2021, the transactions contemplated by the Agreement and Plan of Merger, as amended on May 14, 2021, by and among NextGen, Sky Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of NextGen (“Merger Sub”), and Xos, Inc., a Delaware corporation (now known as Xos Fleet, Inc., “Legacy Xos”), were consummated (the “Closing”), whereby Merger Sub merged with and into Legacy Xos, the separate corporate existence of Merger Sub ceased and Legacy Xos became the surviving corporation and a wholly owned subsidiary of NextGen (such transaction the “Merger” and, collectively with the Domestication, the “Business Combination”). As a result, Xos became the publicly traded entity listed on the Nasdaq Global Market.
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. They do not include all of the information and footnotes required by U.S. GAAP for complete audited financial statements. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Legacy Xos and Xos Services. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (primarily consisting of normal accruals) considered for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the years ended December 31, 2022 and 2021 presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023.
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenues and expenses during the reporting periods. The areas with significant estimates and judgments include, among others, inventory valuation, incremental borrowing rates for assessing operating and financing lease liabilities, useful lives of property and equipment, contingent earn-out shares liability, stock-based compensation, valuation of convertible debt and related embedded derivatives, common stock warrant liability and product warranty liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.
Accounts Receivable, Net	The Company records unsecured and non-interest bearing accounts receivable at the gross invoice amount, net of any allowance for expected credit losses. The Company maintains its allo wance for expected credit losses at a level considered adequate to provide for potential account losses on the balance based on management’s evaluation of past losses, current customer conditions, and the anticipated impact of current economic conditions. The Company recorded an allowance for expected credit losses of $39,000 as of March 31, 2023. No allowance for doubtful accounts was recorded as of March 31, 2022.
Investments in Marketable Debt Securities, Available-for-Sale	The Company maintains a portfolio of investments in a variety of fixed and variable rate debt securities, including U.S. treasuries, corporate debt, asset-backed securities and other, non-U.S. government and supranational bonds and certificate of deposit. The Company considers its investments in marketable debt securities to be available-for-sale, and accordingly, are recorded at their fair values. The Company determines the appropriate classification of investments in marketable debt securities at the ti me of purchase. Unrealized gains and losses on marketable debt securities, available-for-sale are recorded in Accumulated other comprehensive loss which is included within stockholders’ equity. Interest along with amortization of purchase premiums and accretion of discounts from the purchase date through the estimated maturity date, including consideration of variable maturities and contractual call provisions, are included in other income (expenses), net in the condensed consolidated statements of operations and comprehensive loss. Realized gains and losses on the sale of marketable debt securities, available-for-sale are recorded in Other (expense) income, net. The Company typically invests in highly-rated debt securities, and its investment policy generally limits the amount of credit exposure to any one issuer. The policy requires substantially all investments to be investment grade, with the primary objective of minimizing the potential risk of principal loss. See Note 8 — Investments for additional information.
Warranty Liability	The Company provides customers with a product warranty that assures that the products meet standard specifications and are free for periods typically between 2 to 5 years. The Company accrues warranty reserve for the products sold, which includes its best estimate of the projected costs to repair or replace items under warranties and recalls if identified. These estimates are based on actual claims incurred to date and an estimate of the nature, frequency and costs of future claims. These estimates are inherently uncertain given the Company’s relatively short history of sales, and changes to its historical or projected warranty experience may cause material changes to the warranty reserve in the future. Claims incurred under the Company’s standard product warranty programs are recorded based on open claims. The Company recorded warranty liability within other current liabilities in the consolidated balance sheets as of March 31, 2023 and December 31, 2022.
Concentrations of Credit and Business Risk	Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of March 31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. During the three months ended March 31, 2023, one customer accounted for 82% of the Company’s revenues (gross of customer returns) . During the three months ended March 31, 2022, three customers accounted for 24%, 11%, and 10% of the Company’s revenues . As of March 31, 2023, two customers accounted for 59% and 15% of the Company’s accounts receivable. As of March 31, 2023, four customers accounted for 13%, 11%, 11%, and 11% of the Company’s accounts receivable.
Recent Accounting Pronouncements Issued and Adopted and Recent Accounting Pronouncements Issued and Not Yet Adopted	The Company adopted ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), as amended, on January 1, 2023 using the modified retrospective approach method. As of March 31, 2023 and December 31, 2022 the Company had $27.5 million and $50.6 million, respectively, in marketable debt securities, available for sale which are subject to the new standard. As of January 1, 2023 and March 31, 2023, these marketable debt securities, available for sale have an average credit rating of A and no allowance for expected credit losses has been recorded. Under the modified retrospective approach, the Company would record a cumulative effect adjustment to retained earnings by recording an initial allowance for credit losses on marketable debt securities, available-for sale. Periods presented that are prior to the adoption date of January 1, 2023 will not be adjusted. ASU 2016-13 replaced the incurred loss impairment model with a methodology that reflects a current expected credit loss and made targeted changes to the impairment model for available-for-sale debt securities. ASU 2016-13 impacted all of the Company’s investments held at fair value, which included its marketable debt securities, available for sale. Upon adoption of ASU 2016-13 on January 1, 2023, no adjustment was recorded by the Company for an initial allowance for credit losses on marketable debt securities, available for sale and there was no cumulative effect adjustment to retained earnings. Subsequent increases or decreases in the allowance for credit losses on marketable debt securities, available for sale will be recorded in the Company's condensed consolidated statements of operations and comprehensive loss.ASU 2016-13 also applied to the Company’s other financial assets including loans, trade receivables and other financial assets that have the contractual right to receive cash. These other financial assets were evaluated and the adoption of ASU 2016-13 did not have a material impact on the Company’s condensed consolidated financial statements.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Product Warranty Liability	The reconciliation of the change in the Company’s product liability balances consisted of the following (in thousands) : March 31, 2023 March 31, 2022 Warranty liability, beginning of period $ 1,099 $ 177 Reduction in liability (payments) (216) — Increase in liability 272 298 Warranty liability, end of period $ 1,155 $ 475

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Disaggregated revenues by major source for the three months ended March 31, 2023 and 2022 consisted of the following ( in thousands ): Three Months Ended March 31, 2023 2022 Product and service revenue Stepvans & vehicle incentives (1) $ 4,262 $ 6,863 Powertrains 5 14 Fleet-as-a-Service 166 95 Total product and service revenue 4,433 6,972 Ancillary revenue 264 59 Total revenues $ 4,697 $ 7,031

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory amounted to $57.0 million and $57.5 million as of March 31, 2023 and December 31, 2022, respectively, and consisted of the following (in thousands) : March 31, 2023 December 31, 2022 Raw materials $ 39,412 $ 40,271 Work in process 3,213 4,618 Finished goods 14,382 12,651 Total inventories $ 57,007 $ 57,540

Selected Balance Sheet Data (Ta

Selected Balance Sheet Data (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets as of March 31, 2023 and December 31, 2022 consisted of the following ( in thousands ): March 31, 2023 December 31, 2022 Prepaid inventories $ 2,263 $ 2,372 Prepaid expenses and other (1) 1,295 1,299 Contract assets 1,132 290 Financed insurance premiums 3,036 2,289 Assets held for sale 750 1,850 Total prepaid expenses and other current assets $ 8,476 $ 8,100 ____________ (1) Primarily relates to prepaid insurance, licenses, subscriptions, contract assets and other receivables.
Schedule of Other Current Liabilities	Other current liabilities as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 December 31, 2022 Accrued expenses and other (1) $ 7,232 $ 7,589 Contract liabilities 764 193 Customer deposits 1,194 721 Warranty liability 1,155 1,099 Equipment notes payable 314 303 Short-term insurance financing notes 2,824 2,065 Operating lease liabilities, current 1,557 1,530 Finance lease liabilities, current 2,128 2,116 Total other current liabilities $ 17,168 $ 15,616 ____________ (1) Primarily relates to accrued inventory purchases, personnel costs, wages, health benefits, vacation and other accruals.
Schedule of Other Noncurrent Liabilities	Other non-current liabilities as of March 31, 2023 and December 31, 2022 consisted of the following ( in thousands ) March 31, 2023 December 31, 2022 Accrued interest expense $ 1,277 $ 784 Equipment notes payable, non-current 860 942 Operating lease liabilities, non-current 4,770 5,174 Finance lease liabilities, non-current 3,560 4,100 Total other non-current liabilities $ 10,467 $ 11,000

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Amortized Cost, Gross Unrealized Gains/Losses In Accumulated Other Comprehensive Loss And Fair Value Of Marketable Debt Securities, Available-For-Sale	Amortized cost, gross unrealized gains/losses in accumulated other comprehensive loss and fair value of marketable debt securities, available-for-sale, by type of security as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: Corporate debt security $ 24,185 $ — $ (303) $ 23,882 U.S. treasuries 651 — (1) 650 Asset-backed security and other 3,029 — (33) 2,996 $ 27,865 $ — $ (337) $ 27,528 December 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: Corporate debt security $ 40,177 $ — $ (612) $ 39,565 U.S. treasuries 2,201 — (21) 2,180 Asset-backed security and other 5,324 — (76) 5,248 Non-U.S. government and supranational bonds 3,685 — (30) 3,655 $ 51,387 $ — $ (739) $ 50,648 As of March 31, 2023, no allowance for credit losses was recorded related to an impairment of available-for-sale securities.
Schedule of Marketable Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value	The Company’s investments in marketable debt securities, available-for-sale that have been in a continuous unrealized loss position by type of security as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt security $ 405 $ — $ 23,477 $ (303) $ 23,882 $ (303) U.S. treasuries — — 650 (1) 650 (1) Asset-backed security and other — — 2,996 (33) 2,996 (33) $ 405 $ — $ 27,123 $ (337) $ 27,528 $ (337) December 31, 2022 Less than 12 months 12 months or greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Corporate debt security $ 1,790 $ (2) $ 37,775 $ (610) $ 39,565 $ (612) U.S. treasuries — — 2,180 (21) 2,180 (21) Asset-backed security and other — — 5,248 (76) 5,248 (76) Non-U.S. government and supranational bonds — — 3,655 (30) 3,655 (30) $ 1,790 $ (2) $ 48,858 $ (737) $ 50,648 $ (739)
Schedule of Realized Gain (Loss)	Gross realized gains and gross realized losses from the sales of the Company’s marketable debt securities, available-for-sale for the three months ended March 31, 2023 and 2022 consisted of the following (in thousands) : Three Months Ended March 31, 2023 2022 Gross realized gains $ — $ — Gross realized losses $ (91) $ (6)
Schedule of Amortized Cost And Fair Value Of Marketable Debt Securities, Available-For-Sale By Contractual Maturity	Amortized cost and fair value of marketable debt securities, available-for-sale by contractual maturity as of March 31, 2023 consisted of the following ( in thousands , except weighted average data): Amortized Cost Fair Value Due in one year or less $ 27,865 $ 27,528 Weighted average contractual maturity 0.3 years Amortized cost and fair value of marketable debt securities, available-for-sale by contractual maturity as of December 31, 2022 consisted of the following ( in thousands , except weighted average data): Amortized Cost Fair Value Due in one year or less $ 51,387 $ 50,648 Weighted average contractual maturity 0.3 years

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	Stock option activity during the three months ended March 31, 2023 consisted of the following: Options Weighted Average Fair Value Weighted Average Exercise Price Weighted Average Remaining Years Intrinsic Value December 31, 2022 — Options outstanding 1,572,451 $ 0.02 $ 0.02 7.14 $ 670,451 Granted — — — Exercised 1,647 0.02 0.02 Forfeited 808 0.02 0.02 March 31, 2023 — Options outstanding 1,569,996 $ 0.02 $ 0.02 6.90 $ 798,297 March 31, 2023 — Options vested and exercisable 1,105,080 $ 0.02 $ 0.02 6.74 $ 562,066
Schedule of Restricted Stock Units (RSUs) Activity	RSU activity during the three months ended March 31, 2023 consisted of the following: RSUs Weighted Average Grant Date Fair Value Weighted Average Fair Value December 31, 2022 — RSUs outstanding 10,308,272 $ 1.45 $ 4,565,534 Granted 1,156,455 $ 0.83 $ 969,652 Vested 1,590,991 $ 1.02 $ 1,089,668 Forfeited 650,204 $ 1.21 $ 514,189 March 31, 2023 — RSUs outstanding 9,223,532 $ 1.47 $ 4,842,354
Schedule of Recognized Stock-Based Compensation Expense in the Consolidated Statements of Operations and Comprehensive Income (Loss)	The Company recognized stock-based compensation expense (including earn-out RSUs) in the condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023, and 2022 totaling approximately $2.0 million and $1.4 million, respectively, which consisted of the following ( in thousands) : Three Months Ended March 31, 2023 2022 Cost of goods sold $ 129 $ 29 Research and development 501 261 Sales and marketing 267 58 General and administrative 1,115 1,043 Total stock-based compensation expense $ 2,012 $ 1,391

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following at March 31, 2023 and December 31, 2022 (in thousands) : March 31, 2023 December 31, 2022 Equipment $ 7,595 $ 7,595 Finance lease assets 9,283 9,283 Furniture & fixtures 173 173 Company vehicles 1,451 1,389 Leasehold improvements 1,401 1,401 Computers, software and related equipment 3,057 2,865 Construction in progress 347 346 Property and equipment, gross 23,307 23,052 Accumulated depreciation (5,555) (4,471) Property and equipment, net $ 17,752 $ 18,581

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity	The estimated future payments having a remaining term in excess of one year as of March 31, 2023 were as follows ( in thousands ): Years ended December 31, Minimum Purchase Commitment 2023 (remainder of the year) $ 1,820 2024 1,300 2025 1,300 2026 1,300 2027 1,300 Thereafter 1,300 Total $ 8,320

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss per Share	Basic and diluted net loss per share for the three months ended March 31, 2023 and 2022 consisted of the following ( in thousands , except for per share amounts): Three Months Ended March 31, 2023 2022 Numerator: Net loss $ (24,331) $ (24,030) Net loss attributable to common stockholders, basic (24,331) (24,030) Net loss attributable to common stockholders, diluted (1) $ (24,331) $ (24,030) Denominator: Basic Weighted average shares outstanding, basic 168,829 163,165 Basic net loss per share $ (0.14) $ (0.15) Diluted Weighted average shares outstanding, diluted (1) 168,829 163,165 Diluted net loss per share $ (0.14) $ (0.15) ____________ (1) Net loss attributable to common stockholders, diluted excludes adjustments related to the change in fair value of derivative liabilities, interest expense and amortization of discounts and issuance costs related to Convertible Debentures. Additionally, weighted average shares outstanding, diluted excludes the if-converted shares related to Convertible Debentures. These adjustments were excluded from the calculation of diluted net loss per share as they would have an antidilutive effect (see Note 7 - Convertible Notes ).
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Potential weighted average shares that were excluded from the computation of diluted net income (loss) per share because their effect was anti-dilutive as of March 31, 2023 and 2022 consisted of the following (in thousands) : March 31, 2023 March 31, 2022 Contingent earn-out shares 16,422 16,422 Common stock public and private warrants 18,833 18,833 Restricted stock units 9,224 731 Stock options 1,570 1,813 Convertible debt 50,518 —

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value of a Recurring Basis	Assets and liabilities carried at fair value on a recurring basis as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 Fair Value Level 1 Level 2 Level 3 Financial assets: Cash and Cash Equivalents (1) : Money market funds $ 30,417 $ 30,417 $ — $ — 30,417 30,417 — — Short-Term Investments: U.S. treasuries 650 650 — — Corporate debt security 23,882 — 23,882 — Asset-backed security and other 2,996 — 2,996 — 27,528 650 26,878 — Total financial assets $ 57,945 $ 31,067 $ 26,878 $ — Financial liabilities: Private Placement Warrants $ 7 $ — $ 7 $ — Public Warrants 659 659 — — Derivative Liabilities 497 — — 497 Contingent Earn-out Shares liability 616 — — 616 Total financial liabilities $ 1,779 $ 659 $ 7 $ 1,113 ____________ (1) Included in total cash and cash equivalents in the condensed consolidated balance sheets. December 31, 2022 Fair Value Level 1 Level 2 Level 3 Financial assets: Cash and Cash Equivalents (1) : Money market funds $ 22,481 $ 22,481 $ — $ — Corporate debt security 2,199 2,199 — — 24,680 24,680 — — Short-Term Investments: U.S. treasuries 2,180 2,180 — — Corporate debt security 39,565 — 39,565 — Asset-backed security and other 5,248 — 5,248 — Non-U.S. government and supranational bonds 3,655 — 3,655 — 50,648 2,180 48,468 — Total financial assets $ 75,328 $ 26,860 $ 48,468 $ — Financial liabilities: Private Placement Warrants $ 7 $ — $ 7 $ — Public Warrants 654 654 — — Derivative Liabilities 405 — — 405 Contingent Earn-out Shares liability 564 — — 564 Total financial liabilities $ 1,630 $ 654 $ 7 $ 969 ____________ (1) Included in total cash and cash equivalents in the condensed consolidated balance sheets.
Schedule of Liabilities Measured at Fair Value of a Recurring Basis	Assets and liabilities carried at fair value on a recurring basis as of March 31, 2023 and December 31, 2022 consisted of the following (in thousands) : March 31, 2023 Fair Value Level 1 Level 2 Level 3 Financial assets: Cash and Cash Equivalents (1) : Money market funds $ 30,417 $ 30,417 $ — $ — 30,417 30,417 — — Short-Term Investments: U.S. treasuries 650 650 — — Corporate debt security 23,882 — 23,882 — Asset-backed security and other 2,996 — 2,996 — 27,528 650 26,878 — Total financial assets $ 57,945 $ 31,067 $ 26,878 $ — Financial liabilities: Private Placement Warrants $ 7 $ — $ 7 $ — Public Warrants 659 659 — — Derivative Liabilities 497 — — 497 Contingent Earn-out Shares liability 616 — — 616 Total financial liabilities $ 1,779 $ 659 $ 7 $ 1,113 ____________ (1) Included in total cash and cash equivalents in the condensed consolidated balance sheets. December 31, 2022 Fair Value Level 1 Level 2 Level 3 Financial assets: Cash and Cash Equivalents (1) : Money market funds $ 22,481 $ 22,481 $ — $ — Corporate debt security 2,199 2,199 — — 24,680 24,680 — — Short-Term Investments: U.S. treasuries 2,180 2,180 — — Corporate debt security 39,565 — 39,565 — Asset-backed security and other 5,248 — 5,248 — Non-U.S. government and supranational bonds 3,655 — 3,655 — 50,648 2,180 48,468 — Total financial assets $ 75,328 $ 26,860 $ 48,468 $ — Financial liabilities: Private Placement Warrants $ 7 $ — $ 7 $ — Public Warrants 654 654 — — Derivative Liabilities 405 — — 405 Contingent Earn-out Shares liability 564 — — 564 Total financial liabilities $ 1,630 $ 654 $ 7 $ 969 ____________ (1) Included in total cash and cash equivalents in the condensed consolidated balance sheets.
Schedule of Changes on Fair Value of Financial Liabilities	The changes in the fair value of Level 3 financial liabilities during the three months ended March 31, 2023 consisted of the following (in thousands): Derivative Liabilities on Convertible Debentures Contingent Earn-out Shares Liability Fair value at December 31, 2022 $ 405 $ 564 Recognition of earn-out RSUs — — Change in fair value during the period 92 52 Fair value at March 31, 2023 $ 497 $ 616
Schedule of Fair Value Measurement Inputs and Valuation Techniques	Significant unobservable inputs related to Level 3 earn-out shares liability consisted of the following: March 31, 2023 December 31, 2022 Stock price $0.53 $0.44 Stock price volatility 80% 80% Expected term 3.39 years 3.64 years Risk-free interest rate 3.8% 4.2% Significant unobservable inputs related to Level 3 derivative liabilities consisted of the following: March 31, 2023 December 31, 2022 Stock price $0.53 $0.44 Stock price volatility 80% 80% Expected term 0.62 years 0.86 years Risk-free interest rate 4.8% 4.6%

Description of Business (Detail

Description of Business (Details) - USD ($) $ in Millions	1 Months Ended
	Aug. 31, 2021	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from reverse merger, net	$ 216.7
Cash and investments		$ 64

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Allowance for doubtful accounts	$ (39)	$ 0
Accounting Standards Update 2016-13
Property, Plant and Equipment [Line Items]
Debt securities, available-for-sale	$ 27,500		$ 50,600
Customer 1 | Revenue Benchmark | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage	82%	24%
Customer 1 | Accounts Receivable | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage	59%	13%
Customer 2 | Revenue Benchmark | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage		11%
Customer 2 | Accounts Receivable | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage	15%	11%
Customer 3 | Revenue Benchmark | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage		10%
Customer 3 | Accounts Receivable | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage		11%
Customer 4 | Accounts Receivable | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage		11%
Minimum
Property, Plant and Equipment [Line Items]
Standard product warranty, period of warranty	2 years
Maximum
Property, Plant and Equipment [Line Items]
Standard product warranty, period of warranty	5 years

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Warrant Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Movement in Extended Product Warranty Accrual [Roll Forward]
Warranty liability, beginning of period	$ 1,099	$ 177
Reduction in liability (payments)	(216)	0
Increase in liability	272	298
Warranty liability, end of period	$ 1,155	$ 475

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregated Revenues by Major Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Ancillary revenue	$ 264	$ 59
Total revenues	4,697	7,031
Product and service revenue
Disaggregation of Revenue [Line Items]
Total product and service revenue	4,433	6,972
Stepvans & vehicle incentives(1)
Disaggregation of Revenue [Line Items]
Total product and service revenue	4,262	6,863
Powertrains
Disaggregation of Revenue [Line Items]
Total product and service revenue	5	14
Fleet-as-a-Service
Disaggregation of Revenue [Line Items]
Total product and service revenue	$ 166	$ 95

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories	$ 57,007	$ 57,540

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 39,412	$ 40,271
Work in process	3,213	4,618
Finished goods	14,382	12,651
Total inventories	$ 57,007	$ 57,540

Selected Balance Sheet Data - P

Selected Balance Sheet Data - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid inventories	$ 2,263	$ 2,372
Prepaid expenses and other	1,295	1,299
Contract assets	1,132	290
Financed insurance premiums	3,036	2,289
Assets held for sale	750	1,850
Total prepaid expenses and other current assets	$ 8,476	$ 8,100

Selected Balance Sheet Data - O

Selected Balance Sheet Data - Other Current Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued expenses and other	$ 7,232	$ 7,589
Contract liabilities	764	193
Customer deposits	1,194	721
Warranty liability	1,155	1,099
Equipment notes payable	314	303
Short-term insurance financing notes	2,824	2,065
Operating lease liabilities, current	1,557	1,530
Finance lease liabilities, current	2,128	2,116
Total other current liabilities	17,168	$ 15,616
Revenue recognized from customer deposits	$ 200

Selected Balance Sheet Data -_2

Selected Balance Sheet Data - Other Non-Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued interest expense	$ 1,277	$ 784
Equipment notes payable, non-current	860	942
Operating lease liabilities, non-current	4,770	5,174
Finance lease liabilities, non-current	$ 3,560	$ 4,100
Finance lease, liability, noncurrent, statement of financial position [extensible enumeration]	Total other non-current liabilities	Total other non-current liabilities
Total other non-current liabilities	$ 10,467	$ 11,000

Earn-out Shares Liability (Deta

Earn-out Shares Liability (Details) $ / shares in Units, $ in Thousands		3 Months Ended
	Aug. 20, 2021 day $ / shares shares	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, shares (in shares) | shares	16,200,000
Earn-out shares liability | $		$ 616		$ 564
Change in fair value of earn-out shares liability | $		$ (52)	$ 2,624
Derivative Instrument, Tranche One
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, shares (in shares) | shares	5,400,000
Derivative instrument, contingent consideration, liability, earnout period, stock price trigger (in dollars per share)	$ 14
Threshold trading days | day	10
Threshold trading day period | day	20
Earn-out period	5 years
Derivative Instrument, Tranche One | Minimum
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, earnout period, stock price trigger (in dollars per share)	$ 14
Derivative Instrument, Tranche One | Maximum
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, earnout period, stock price trigger (in dollars per share)	$ 20
Derivative Instrument, Tranche Two
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, shares (in shares) | shares	5,400,000
Derivative instrument, contingent consideration, liability, earnout period, stock price trigger (in dollars per share)	$ 20
Threshold trading days | day	10
Threshold trading day period | day	20
Derivative Instrument, Tranche Two | Minimum
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, earnout period, stock price trigger (in dollars per share)	$ 20
Derivative Instrument, Tranche Two | Maximum
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, earnout period, stock price trigger (in dollars per share)	$ 25
Derivative Instrument, Tranche Three
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, shares (in shares) | shares	5,400,000
Derivative instrument, contingent consideration, liability, earnout period, stock price trigger (in dollars per share)	$ 25
Threshold trading days | day	10
Threshold trading day period | day	20
Restricted Stock Units (RSUs)
Schedule Of Recapitalization [Line Items]
Derivative instrument, contingent consideration, liability, shares (in shares) | shares	261,000

Convertible Notes - Narrative (

Convertible Notes - Narrative (Details)			3 Months Ended		12 Months Ended
	Sep. 09, 2022 USD ($)	Aug. 11, 2022 USD ($)	Mar. 31, 2023 USD ($) vehicle $ / shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Sep. 21, 2022 USD ($)	Aug. 09, 2022 USD ($)
Debt Instrument [Line Items]
Debt instrument, face amount		$ 20,000,000				$ 15,000,000	$ 35,000,000
Temporary equity, conversion of convertible securities	$ 2,000,000
Debt instrument, term	30 days
Interest rate, stated percentage			10%
Debt conversion, converted instrument, rate			10%
Convertible debt remaining percent			7.50%
Common stock, convertible, conversion price, increase (in dollars per share) | $ / shares			$ 2.4733
Debt, weighted average interest rate			97%
Redemption, stock price threshold (in dollars per share) | $ / shares			$ 0.50
Derivative liabilities			$ 497,000		$ 405,000
Change in fair value of derivative instruments			$ 97,000	$ 435,000
Proceeds from issuance of convertible notes		$ 20,000,000
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average remaining contractual term			10 days
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares			$ 2.3817
Securities Purchase Agreement
Debt Instrument [Line Items]
Equity method investment, ownership percentage			9.99%
Convertible Debt
Debt Instrument [Line Items]
Redemption, stock price threshold (in dollars per share) | $ / shares			$ 0.59
Debt instrument, redemption price, percentage			5%
Debt instrument, convertible, threshold consecutive trading days | vehicle			5
Common stock available under the exchange cap			95%
Debt instrument, increase, accrued interest			$ 1,000,000
Derivative, floor interest rate			85%
Debt instrument, periodic payment, principal			$ (9,000,000)
Debt instrument, periodic payment			$ (500,000)
Original issuance discount percentage			2%
Proceeds from issuance of convertible notes			$ 34,300,000
Debt issuance costs, net			(300,000)
Convertible debt			24,000,000		33,000,000
Amortization of debt issuance costs			(4,400,000)		(6,200,000)
Convertible Debt | Maximum
Debt Instrument [Line Items]
Debt instrument, increase, accrued interest			4,000,000
Convertible Debt | Other Nonoperating Income (Expense)
Debt Instrument [Line Items]
Amortization of debt issuance costs			(1,800,000)
Unrecognized tax benefits, interest on income taxes accrued			400,000
Convertible Notes Payable
Debt Instrument [Line Items]
Debt instrument, face amount			$ 20,000,000		20,000,000
Interest rate, stated percentage			6%
Debt issuance costs, net			$ (100,000)
Amortization of debt issuance costs			(100,000)		$ (100,000)
Unrecognized tax benefits, interest on income taxes accrued			$ 500,000
Convertible Notes Payable | Securities Purchase Agreement
Debt Instrument [Line Items]
Equity method investment, ownership percentage			19.99%

Investments - Amortized Cost, G

Investments - Amortized Cost, Gross Unrealized Gains/Losses In Accumulated Other Comprehensive Loss And Fair Value Of Marketable Debt Securities, Available-For-Sale (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Short-term investments:
Amortized Cost	$ 27,865	$ 51,387
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(337)	(739)
Fair Value	27,528	50,648
Corporate debt security
Short-term investments:
Amortized Cost	24,185	40,177
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(303)	(612)
Fair Value	23,882	39,565
U.S. treasuries
Short-term investments:
Amortized Cost	651	2,201
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(1)	(21)
Fair Value	650	2,180
Asset-backed security and other
Short-term investments:
Amortized Cost	3,029	5,324
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(33)	(76)
Fair Value	$ 2,996	5,248
Non-U.S. government and supranational bonds
Short-term investments:
Amortized Cost		3,685
Gross Unrealized Gains		0
Gross Unrealized Losses		(30)
Fair Value		$ 3,655

Investments - Continuous Unreal

Investments - Continuous Unrealized Loss Position (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value
Less than 12 months	$ 405	$ 1,790
12 months or greater	27,123	48,858
Total	27,528	50,648
Gross Unrealized Losses
Less than 12 months	0	(2)
12 months or greater	(337)	(737)
Total	(337)	(739)
Corporate debt security
Fair Value
Less than 12 months	405	1,790
12 months or greater	23,477	37,775
Total	23,882	39,565
Gross Unrealized Losses
Less than 12 months	0	(2)
12 months or greater	(303)	(610)
Total	(303)	(612)
U.S. treasuries
Fair Value
Less than 12 months	0	0
12 months or greater	650	2,180
Total	650	2,180
Gross Unrealized Losses
Less than 12 months	0	0
12 months or greater	(1)	(21)
Total	(1)	(21)
Asset-backed security and other
Fair Value
Less than 12 months	0	0
12 months or greater	2,996	5,248
Total	2,996	5,248
Gross Unrealized Losses
Less than 12 months	0	0
12 months or greater	(33)	(76)
Total	$ (33)	(76)
Non-U.S. government and supranational bonds
Fair Value
Less than 12 months		0
12 months or greater		3,655
Total		3,655
Gross Unrealized Losses
Less than 12 months		0
12 months or greater		(30)
Total		$ (30)

Investments - Gross Realized Ga

Investments - Gross Realized Gains (Losses) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Gross realized gains	$ 0	$ 0
Gross realized losses	$ (91)	$ (6)

Investments - Amortized Cost an

Investments - Amortized Cost and Fair Value of Marketable Debt Securities, Available-for-sale by Contractual Maturity (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Amortized Cost
Due in one year or less	$ 27,865	$ 51,387
Fair Value
Due in one year or less	$ 27,528	$ 50,648
Weighted average contractual maturity	3 months 18 days	3 months 18 days

Equity (Details)

Equity (Details) $ / shares in Units, $ in Millions		3 Months Ended	12 Months Ended
	Mar. 23, 2022 USD ($) shares	Mar. 31, 2023 USD ($) vote $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares
Stockholders' Equity And Temporary Equity [Line Items]
Stock authorized (in shares)		1,010,000,000
Common stock, authorized (in shares)		1,000,000,000	1,000,000,000
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)		10,000,000	10,000,000
Preferred stock, par value (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Number of votes per share | vote		1
Sale of stock, remaining commitment amount available | $		$ 120.7	$ 120.7
Standby Equity Purchase Agreement
Stockholders' Equity And Temporary Equity [Line Items]
Sale of stock, consideration received on transaction | $	$ 125
Request period in force	36 months
Sale of stock, number of shares issued in transaction (in shares)	18,582

Derivative Instruments (Details

Derivative Instruments (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) day $ / shares shares
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Redemption, stock price threshold (in dollars per share)	$ 0.50
Threshold consecutive trading days ending on the third day prior to notice of redemption	10 days
Warrant Redemption Scenario One
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Redemption, stock price threshold (in dollars per share)	$ 18
Redemption price (in dollars per share)	$ 0.01
Redemption notice period	30 days
Redemption, threshold trading days | day	20
Redemption, threshold consecutive trading days	30 days
Redemption period	30 days
Warrant Redemption Scenario Two
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Redemption, stock price threshold (in dollars per share)	$ 10
Redemption price (in dollars per share)	$ 0.10
Redemption notice period	30 days
Reference value (in dollars per share)	$ 18
Public Warrants
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of warrants issued (in shares) | shares	18,633,301,000
Warrants outstanding fair value | $	$ 700,000
Exercise price of warrants or rights (in dollars per share)	$ 11.50
Private Placement Warrants
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of warrants issued (in shares) | shares	199,997,000
Warrants outstanding fair value | $	$ 7,000

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)			1,572,451,000
Aggregate intrinsic value of options exercised	$ 800	$ 1,000
Options, granted (in shares)	0	0
Stock-based compensation expense	$ 2,012,000	$ 1,391,000
Unamortized stock-based compensation	$ 12,100,000
Unamortized stock-based compensation, weighted average remaining amortization period	2 years 6 months 10 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested in period, intrinsic value	$ 1,089,668
2018 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)	0
Options outstanding (in shares)	1,569,996,000
Expiration period	10 years
Vesting period	4 years
2021 Equity Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	20,701,956
Share-based Payment Arrangement, Tranche One | 2018 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25%
Share-based Payment Arrangement, Tranche Two | 2018 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	36 months

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options Activity (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Options
Options, outstanding beginning balance (in shares)	1,572,451,000
Options, granted (in shares)	0	0
Stock options exercised (in shares)	1,647,000
Options, forfeited (in shares)	808,000
Options, outstanding ending balance (in shares)			1,572,451,000
Options vested and exercisable (in shares)	1,105,080,000
Weighted Average Fair Value
Options outstanding beginning balance (in dollars per share)	$ 20
Options granted, weighted average grant date fair value (in dollars per share)	0
Options, exercised, weighted average grant date fair value (in dollars per share)	20
Options, forfeited in period, weighted average grant date fair value (in dollars per share)	20
Options outstanding ending balance (in dollars per share)	20		$ 20
Options, vested and exercisable, weighted average grant date fair value (in dollars per share)	20
Weighted Average Exercise Price
Options, outstanding, beginning balance, weighted average exercise price (in dollars per share)	20
Options, granted, weighted average exercise price (in dollars per share)	0
Options, exercised, weighted average exercise price (in dollars per share)	20
Options, forfeited, weighted average exercise price (in dollars per share)	20
Options, outstanding, ending balance, weighted average exercise price (in dollars per share)	20		$ 20
Options, exercisable, weighted average exercise price (in dollars per share)	$ 20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	6 years 10 months 24 days		7 years 1 month 20 days
Options, exercisable, weighted average remaining contractual term	6 years 8 months 26 days
Options outstanding, intrinsic value	$ 798,297		$ 670,451
Options, exercisable, intrinsic value	$ 562,066

Stock-Based Compensation - RSU

Stock-Based Compensation - RSU Activity (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
RSUs
Beginning balance, outstanding (in shares) | shares	10,308,272
Granted in period (in shares) | shares	1,156,455
Vested in period (in shares) | shares	1,590,991
Forfeited in period (in shares) | shares	650,204
Ending balance, outstanding (in shares) | shares	9,223,532
Weighted Average Grant Date Fair Value
Beginning balance, outstanding (in dollars per share) | $ / shares	$ 1.45
Granted in period (in dollars per share) | $ / shares	0.83
Vested in period (in dollars per share) | $ / shares	1.02
Forfeitures (in dollars per share) | $ / shares	1.21
Ending balance, outstanding (in dollars per share) | $ / shares	$ 1.47
Weighted Average Fair Value
Beginning balance | $	$ 4,565,534
Granted | $	969,652
Vested | $	1,089,668
Forfeited | $	514,189
Ending balance | $	$ 4,842,354

Stock-Based Compensation - Reco

Stock-Based Compensation - Recognized Stock-based Compensation Expense Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,012	$ 1,391
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	129	29
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	501	261
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	267	58
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,115	$ 1,043

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Finance lease assets	$ 9,283	$ 9,283
Property and equipment, gross	23,307	23,052
Accumulated depreciation	(5,555)	(4,471)
Property and equipment, net	17,752	18,581
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,595	7,595
Furniture & fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	173	173
Company vehicles
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,451	1,389
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,401	1,401
Computers, software and related equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,057	2,865
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 347	$ 346

Property and Equipment, Net - N

Property and Equipment, Net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 1	$ 0.3

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023 (remainder of the year)	$ 1,820
2024	1,300
2025	1,300
2026	1,300
2027	1,300
Thereafter	1,300
Total	$ 8,320

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party		$ 35
Affiliated Entity
Related Party Transaction [Line Items]
Related party transaction, expenses from transactions with related party	$ 200	$ 200

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate, percent	0%	0%

Net Loss per Share - Computatio

Net Loss per Share - Computation of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net loss	$ (24,331,000)	$ (24,030,000)
Net loss attributable to common stockholders, basic	(24,331,000)	(24,030,000)
Net loss attributable to common stockholders, diluted	$ (24,331,000)	$ (24,030,000)
Denominator:
Weighted average shares outstanding — basic (in shares)	168,829,000	163,165,000
Net loss per share — basic (in dollar per share)	$ (0.14)	$ (0.15)
Dilutive effect
Weighted average shares outstanding — diluted (in shares)	168,829,000	163,165,000
Net loss per share — diluted (in dollar per share)	$ (0.14)	$ (0.15)

Net Loss per Share - Potential

Net Loss per Share - Potential Weighted Average Shares That Were Excluded From The Computation Of Diluted Net Income (Loss) Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Contingent earn-out shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares that were excluded from the computation of diluted net loss per share (in shares)	16,422	16,422
Common stock public and private warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares that were excluded from the computation of diluted net loss per share (in shares)	18,833	18,833
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares that were excluded from the computation of diluted net loss per share (in shares)	9,224	731
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares that were excluded from the computation of diluted net loss per share (in shares)	1,570	1,813
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares that were excluded from the computation of diluted net loss per share (in shares)	50,518	0

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 27,528,000	$ 50,648,000
Common stock warrant liability	666,000	661,000
Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	7,000
Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	700,000
U.S. treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	650,000	2,180,000
Corporate debt security
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	23,882,000	39,565,000
Asset-backed security and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	2,996,000	5,248,000
Non-U.S. government and supranational bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		3,655,000
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	30,417,000	24,680,000
Short-term investments	27,528,000	50,648,000
Total financial assets	57,945,000	75,328,000
Common stock warrant liability	497,000	405,000
Contingent Earn-out Shares liability	616,000	564,000
Total financial liabilities	1,779,000	1,630,000
Fair Value, Recurring | Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	7,000	7,000
Fair Value, Recurring | Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	659,000	654,000
Fair Value, Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	30,417,000	22,481,000
Fair Value, Recurring | U.S. treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	650,000	2,180,000
Fair Value, Recurring | Corporate debt security
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		2,199,000
Short-term investments	23,882,000	39,565,000
Fair Value, Recurring | Asset-backed security and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	2,996,000	5,248,000
Fair Value, Recurring | Non-U.S. government and supranational bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		3,655,000
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	30,417,000	24,680,000
Short-term investments	650,000	2,180,000
Total financial assets	31,067,000	26,860,000
Common stock warrant liability	0	0
Contingent Earn-out Shares liability	0	0
Total financial liabilities	659,000	654,000
Fair Value, Recurring | Level 1 | Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	0	0
Fair Value, Recurring | Level 1 | Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	659,000	654,000
Fair Value, Recurring | Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	30,417,000	22,481,000
Fair Value, Recurring | Level 1 | U.S. treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	650,000	2,180,000
Fair Value, Recurring | Level 1 | Corporate debt security
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		2,199,000
Short-term investments	0	0
Fair Value, Recurring | Level 1 | Asset-backed security and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring | Level 1 | Non-U.S. government and supranational bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		0
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	26,878,000	48,468,000
Total financial assets	26,878,000	48,468,000
Common stock warrant liability	0	0
Contingent Earn-out Shares liability	0	0
Total financial liabilities	7,000	7,000
Fair Value, Recurring | Level 2 | Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	7,000	7,000
Fair Value, Recurring | Level 2 | Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	0	0
Fair Value, Recurring | Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Fair Value, Recurring | Level 2 | U.S. treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring | Level 2 | Corporate debt security
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		0
Short-term investments	23,882,000	39,565,000
Fair Value, Recurring | Level 2 | Asset-backed security and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	2,996,000	5,248,000
Fair Value, Recurring | Level 2 | Non-U.S. government and supranational bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		3,655,000
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Total financial assets	0	0
Common stock warrant liability	497,000	405,000
Contingent Earn-out Shares liability	616,000	564,000
Total financial liabilities	1,113,000	969,000
Fair Value, Recurring | Level 3 | Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	0	0
Fair Value, Recurring | Level 3 | Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liabilitites	0	0
Fair Value, Recurring | Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Fair Value, Recurring | Level 3 | U.S. treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Recurring | Level 3 | Corporate debt security
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		0
Short-term investments	0	0
Fair Value, Recurring | Level 3 | Asset-backed security and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 0	0
Fair Value, Recurring | Level 3 | Non-U.S. government and supranational bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments		$ 0

Fair Value Measurements - Chang

Fair Value Measurements - Changes in the Fair Value of the Financial Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Derivative Liabilities on Convertible Debentures
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 405
Recognition of earn-out RSUs	0
Change in fair value during the period	92
Ending Balance	497
Contingent Earn-out Shares Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	564
Recognition of earn-out RSUs	0
Change in fair value during the period	52
Ending Balance	$ 616

Fair Value Measurements - Signi

Fair Value Measurements - Significant Unobservable Inputs Related To Level 3 Earn-Out Shares Liability (Details) - Level 3	Mar. 31, 2023	Dec. 31, 2022
Stock price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out shares, liability, measurement input	0.53	0.44
Derivative Liability, Measurement Input	0.53	0.44
Stock price volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out shares, liability, measurement input	0.80	0.80
Derivative Liability, Measurement Input	0.80	0.80
Expected term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out shares, liability, measurement input	3.39	3.64
Derivative Liability, Measurement Input	0.62	0.86
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Earn-out shares, liability, measurement input	0.038	0.042
Derivative Liability, Measurement Input	0.048	0.046

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - VWAP - USD ($)	May 04, 2023	May 11, 2023
Subsequent Event [Line Items]
Sale of stock, maximum amount of consideration to be received on transaction	$ 3,100,000
Debt instrument, floor price		$ 0.59